Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganin for drug discovery and mechanism of action (MOA) research

Pre-Made Citatuzumab Bogatox biosimilar, Fusion Protein, Citatuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Bougainvillea spectabilis Willd bouganin is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Citatuzumab bogatox (VB6-845) is a monoclonal antibody Fab fragment fused with bouganin, a ribosome inactivating protein from the plant Bougainvillea spectabilis.[1] It has undergone preclinical development for the treatment of ovarian cancer and other solid tumors.[2]